Current status and perspectives in clinical treatment of intermediate and advanced primary hepatocellular carcinoma
Given the high incidence of hepatocellular carcinoma and the high detection rate of intermediate and advanced liver cancer in China,patients have lost the opportunity of surgical resection of cancer tissue when they see a doctor.However,in clinical practice,single treatment for unresectable liver cancer patients often fails to obtain good prognosis,and the 5-year survival rate is low.Therefore,standardized comprehensive treatment is urgently needed to improve the overall survival of patients with advanced liver cancer.By reviewing the clinical trials conducted at home and abroad for the treatment of patients with intermediate and advanced liver cancer,it is found that Atezolizumab combined with Bevacizumab is significantly superior to single-agent Nivolumab and Pembrolizumab in terms of overall survival,disease-free progression and adverse drug reaction incidence in patients with unresectable advanced liver cancer.Meanwhile,Regorafenib targeted treatment for patients with Sorafenib-resistant liver cancer also achieves a longer median survival time.Because immunotherapy or targeted therapy alone can not meet the requirements of disease-free survival in patients with advanced liver cancer,interventional surgery combined with immunotherapy or targeted therapy can significantly shorten the total treatment time of patients,and the adverse drug reaction grade is lower,increasing patient compliance.Summarizing and analyzing the results of existing clinical drug trials is of important significance for improving the drug benefit rate and reducing adverse reactions of liver cancer patients.
万方数据
维普
